Search Results

Findings Published From Initial Cases With Neovasc's Tiara TMVR Device

October 22, 2018—Neovasc Inc. announced the publication of findings from the initial experiences of transcatheter mitral valve replacement (TMVR) using the company's Tiara valve in patients with previous aortic valve replacement.

Neovasc's Tiara System Early Data Presented in a Conference Tutorial Session

November 19, 2019—Neovasc, Inc. announced its Tiara transfemoral/transseptal (TF/TS) system was featured in a tutorial session focusing on the early clinical outcomes for patients undergoing transcatheter mitral valve replacement at the PCR London Valves 2019 meeting, held November 17–19 in London, England.

Neovasc Announces First-in-Human Implantation of Tiara Transcatheter Mitral Valve

February 3, 2014—Neovasc Inc. (Vancouver, BC, Canada) announced that the first-in-human implantation of the self-expanding Tiara transcatheter mitral valve was performed on January 30 at St.

IDE Approved for Trial of Neovasc's Tiara Transcatheter Mitral Valve

October 9, 2014—Neovasc Inc. announced that it has received conditional investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate the United States arm of its TIARA-I early feasibility trial.

St. Jude Medical's Portico Transcatheter Aortic Heart Valve Receives CE Mark Approval

November 19, 2012—St.

Neovasc Reports on Tiara Clinical Investigation Program

September 12, 2017—Neovasc Inc. announced an update on the study of the company's Tiara valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with mitral regurgitation (MR).